Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'.

Abstract excerpt

With each failure of anti-amyloid-β therapy in clinical trials, new trials are initiated with no hint of slowing down. This may be due, in part, to the fact that the amyloid cascade hypothesis has been so modified over time that it is now impossible to confirm or deny. The hypothesis now states, in effect, that invisible molecules target invisible structures. Still relevant, however, are multiple factors that...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Alzheimer Disease
• Share to Amyloid beta-Peptides